EBOLA UPDATED!! jul30 READ ALL::::EBOLA Detection kits Deployed To National Guard in All 50 States

http://survivalbackpack.us/ebola-detection-kits-deployed-national-guard-units-50-states/


:NOTE THE DATE, THEY KNEW IT WAS COMING BACK IN APRIL-I'D SAY INTENTIONAL RELEASE-HOW ABOUT YOU? Steve Quayle


EBOLA Detection Kits Deployed To National Guard Units In All 50 States
Posted on April 11, 2014  by  SurvivalBackpack • 14 comments


(POTR)  On April 8th Congress was informed by the the Department of Defense [DoD] that because of emerging threats JBAIDS hemorrhagic fever assays have been deployed to National Guard units of all 50 States.
“By partnering with the U.S. Army Medical Research and Materiel Command and the Food and Drug Administration, we have made accessible additional diagnostic assays for high consequence, low probability biological threat agents for use during declared public health emergencies. This collaboration has facilitated the availability of viral hemorrhagic fever diagnostic assays for use during a declared emergency and adds previously unavailable preparedness capabilities to this fielded system…

To address the need for a near term capability to combat emerging threat materials, we have already provided Domestic Response Capability kits to the National Guard weapons of mass destruction civil support teams resident in all 50 states. These kits provide emerging threat mitigation capability that includes detection, personnel protection, and decontamination.”

It is unclear how real or imminent the threat may be, but it is clear that a massive surge of Governmental spending and preparedness has occurred since Hemorrhagic H7N9 Bird Flu came on the scene in 2013 and those preparedness activities are accelerating as EBOLA has started to gain momentum in Africa. (see links below)

There are multiple vignettes one could put forth for these governmental activities ranging from simple wasteful defense spending, to airborne mutated EBOLA, or an expected biological first strike prelude to WW3. The preparations seem to lean towards the latter. Rather than worry about the situation, the best course of action is be aware of the unusual military equipment which would be utilized in a defense situation, as such information will provide leading edge risk mitigation actionable information to threats that may result in mass panic or mass quarantine.


In that regard, spotting the field use of the biomedical equipment shown below is an extremely strong indicator that a Biodefense operation is underway. Pay special attention to the JBAIDS device shown below, its presence at any medical or field facility is prima facie evidence of a high risk medical event of disastrous proportion. For mobile applications the JBAIDS device is carried in the Bio sampling vehicles shown below.
Joint Biological Agent Identification and Diagnostic System [JBAIDS]

 



JOINT BIOLOGICAL POINT DETECTION SYSTEM (JBPDS)



 

Alternate Vehicle

 



Source Information:

HOUSE ARMED SERVICES COMMITTEE 

SUBCOMMITTEE ON INTELLIGENCE, EMERGING THREATS AND CAPABILITIES 

SECOND SESSION, 113TH CONGRESS 



- See more at: http://survivalbackpack.us/ebola-detection-kits-deployed-national-guard-units-50-states/#sthash.sr5tJlux.dpuf

http://www.thecommonsenseshow.com/2014/07/29/the-u-s-is-quietly-establishing-ebola-quarantine-centers/

The U.S. Is Quietly Establishing Ebola Quarantine Centers

29 Jul, 2014 by Dave Hodges
Print this article Font size -16+
Most border crossings in Liberia, located in West Africa, have been closed and communities hit by an Ebola outbreak face quarantine to try to halt the spread of the virus. The symptoms include high fever, bleeding and central nervous system damage. Fatality rates can reach 90% and the incubation period is two to 21 days. THERE IS NO VACCINE OR CURE (CDC).
United States aid worker, Nancy Writebol, a missionary sent by the Calvary Church in North Carolina, became the second American citizen to contract the Ebola.  Previously, Dr Kent Brantly, a doctor also working at an Ebola clinic in the capital of Liberia, Monrovia, had previously been infected with the deadly Ebola virus while treating victims of the disease at a hospital in West Africa. Ebola is transmitted through bodily fluids, stated Tarik Jasarevic, a spokesman for the WHO, said around 100 health workers had been infected by Ebola in three countries. The virus has now killed 660 people across Guinea, Liberia and Sierra Leone since the outbreak began nearly six months ago. Ebola has a mortality of approximately 90% and overwhelms the health care systems of the communities in which it appears.
Containment
The past week has seen Ebola infecting key medical staff in Sierra Leone, a deadly Middle East virus has become airborne and a whole city in China put on lock-down for fear of bubonic plague. Lockdown? What exactly is lockdown? If a community is to stop Ebola, they must go into lockdown procedures. Lockdown procedures include the closing of the border to a present non-infected nation. The map, below, shows the impacted countries experiencing an Ebola outbreak.

Why are we admitting people to the U.S. who are coming from a region with a live Ebola outbreak. Presently, Ebola is not being tested for at the U.S. Border.
Both Dr. Jane Orient, one of Arizona’s top physicians as well as other researchers, such as myself, have received information, from Border Patrol informants, that as many as 100,000 West Africans are being admitted to the United States under the same provisions that President Obama is presently admitting so-called “unaccompanied minors”. These people are from the same region of the world as the uncontained outbreak of Ebola. As Dr. Orient said in her interview on The Common Sense Show, on June 30, 2014, “It is not a matter of if Ebola comes into the United States, but when.”
The United States Containment Procedures
Fortunately, the United States has detailed procedures to deal with a pandemic outbreak and it carries the force of law. Under section 361 of the Public Health Service Act (42 U.S. Code § 264), the U.S. Secretary of Health and Human Services is authorized to take measures to prevent the entry and spread of communicable diseases from foreign countries into the United States and between states. The authority for carrying out these functions on a daily basis has been delegated to the Centers for Disease Control and Prevention (CDC). The CDC utilizes two basic strategies when trying to contain a public outbreak of something as deadly as Ebola and they are Isolation and Quarantine.

Quote :

“Isolation is used to separate ill persons who have a communicable disease from those who are healthy. Isolation restricts the movement of ill persons to help stop the spread of certain diseases. For example, hospitals use isolation for patients with infectious tuberculosis. Quarantine is used to separate and restrict the movement of well persons who may have been exposed to a communicable disease to see if they become ill. These people may have been exposed to a disease and do not know it, or they may have the disease but do not show symptoms. Quarantine can also help limit the spread of communicable disease” (CDC). Quarantining involves the creation of detainment facilities in which people, who are suspected, or are infected with a pathogen, are forcibly detained and not allowed to leave. This statute also applies, in the same manner, as people who “may be exposed”.

 
The United States Is Moving to Establish Quarantine Centers
Even if there was not a present immigration crisis at the border, there is a significant outbreak of Ebola in a seven country region of West Africa. With modern air travel, this government should be enacting protocols to limit the chances for Ebola from coming into the United States. Instead, President Obama is having ICE and DHS load up the busses and planes, at taxpayers expense to ship them throughout the United States without going through a minimum of a three week health screening period (i.e. Ebola’s incubation period). This is highly irresponsible and could be considered to be an act of treason being committed against the people of the United States. Under federally mandated quarantine procedures, here is what the CDC and President Obama are mandated to do in the present crisis. Here is what is supposed to happen as described by the CDC:

Quote :

The Secretary of the Department of Health and Human Services has statutory responsibility for preventing the introduction, transmission, and spread of communicable diseases in the United States. Under its delegated authority, the Division of Global Migration and Quarantine works to fulfill this responsibility through a variety of activities, including

• Quote :

  the operation of Quarantine Stations at ports of entry

  
  

• Quote :

  establishment of standards for medical examination of persons destined for the United States, and

  
  

• Quote :

  administration of interstate and foreign quarantine regulations, which govern the international and interstate movement of persons, animals, and cargo.

  
  

Instead, we are getting this type of Obama led method of pandemic protection, as described below.
Ebola Quarantine Centers
Yesterday, Paul Watson opened a lot of eyes with the following statement: ” The source, an office clerk within the LADHS, said that during a policy meeting on the morning of June 18th last month, his supervisor announced that the Los Angeles County Dept. of Health Services had struck a deal with the government to open up “low cost housing” facilities for homeless people, otherwise known as “FEMA camps.” The source said that his supervisor ordered staff not to use the term “FEMA camps.” One look at who is behind this program should raise the eyebrows of every person. as it is being administered by the Department of Health Services.

Quote :

“In an effort to respond to the high need for recuperative care services, Housing for Health will open a 38 bed recuperative care site in South LA this summer. The goal of recuperative care is to provide short-term housing with health oversight to homeless DHS patients who are recovering from an acute illness or injury or have conditions that would be exacerbated by living on the street or in shelters. The site was renovated to serve patients with mobility impairments and provides wheelchair accessible community space indoors and in an open-air courtyard. The site will be operated by LAMP Community, a non-profit agency with over 25 years of experience providing services to homeless individuals”.

Quote :

At a time when city, state and federal budgets are stretched to infinity, we are supposed to believe that out of the goodness of their hearts, LA County is going to provide these kinds of services at this kind of expense to previously ignored homeless people? Does any of this make any sense given the economic state of the country? Paul Watson is calling these facilities, FEMA camps. I agree with Paul and would also add that they are FEMA Quarantine Camps. This is the early preparation for what is coming. Cities across the country, from Tempe, AZ. to Charleston, SC., are outlawing homeless people as it gives the government to quarantine these people.  A clear pattern is emerging that we are soon going to see from California to South Carolina homeless people being quarantined, held against their will, for “health” reasons. The handling of the present and potential Ebola crisis speaks for itself. When there is trouble America, who are you going to call? Thirty years ago, we called the Ghostbusters (i.e. hit movie 1984), which is a whole lot better than what is available now.

http://www.thecommonsenseshow.com/2014/07/30/ebolas-patient-zero-has-been-identified-global-transmission-has-begun/

EBOLA’S Patient ZERO HAS BEEN IDENTIFIED: GLOBAL TRANSMISSION HAS BEGUN
30 Jul, 2014 by Dave Hodges





It  is now being reported that Patrick Sawyer, whose sister also died from Ebola, was allowed on two ASKY Airlines flights in Liberia while infected witht he deadly virus, Ebola, which painfully kills 90% of its victims.

Patient Zero, Patrick Sawyer, had a layover in Ghana then changed planes in Togo and flew to an international travel hub of Lagos, located in Nigeria. Nigeria is also the site of an Ebola outbreak.  “The dad-of-three died five days after arriving in the city”.  His sister, with whom Sawyer had contact, died of Ebola. He should never have been allowed to board any plane.

A desperate search is on to find the hundreds of passengers who flew on the same jets as Sawyer.  A total of 59 passengers and crew are estimated to have come into contact with Sawyer and effort is being made to track each individual down. There is an inherent problem with this “track down”. Presumably, some of the passengers connected to other flights, which known to be the case. Let’s just say for the sake of argument that only 20 people, a low estimate given the nature of the airports that Sawyer was traveling in, were connecting to other flights, the spread of the virus would quickly expand beyond any possibility of containment because in less than a half a day, nearly a half a million people would be potentially exposed. Within a matter of a couple of hours, Sawyer’s infected fellow travelers would each have made contact with 200 other passengers and crew. Hours later, these flights would land and these people would go home to the friends, families and coworkers across several continents.

The fact is that the window for tracking down Sawyers initial point of contact with the traveling public, has closed. Patient Zero has tipped the very first dominoes in what could prove to be the worst epidemic in human history.
Not to Worry Says the U.S. Government

United States health officials say they are not worried because Ebola is transmitted through exposure to bodily fluids.

“…Witnesses say Sawyer, a 40-year-old Liberian Finance Ministry employee en route to a conference in Nigeria, was vomiting and had diarrhea aboard at least one of his flights with some 50 other passengers aboard. Ebola can be contracted from traces of feces or vomit, experts say”.  I would submit that it is time to get worried. And given the fact that we now know that Ebola detection kits have been deployed in National Guard unit kits in all 50 states.

We are either looking at gross negligence or a well-planned conspiracy.

I can think of a lot more fun ways to get hickies, and that's all that this vacuum jar so-called therapy will do for you. When I see something like this nonsense embedded into an otherwise serious article it causes me to reconsider the entire article. If you click the image in the article it opens a scam doctor video that you can't pause, stop, reverse, or go forward on. I've disabled the hot link in my reproduced image below.

http://www.phac-aspc.gc.ca/lab-bio/res/psds-ftss/ebola-eng.php

EBOLA VIRUS
PATHOGEN SAFETY DATA SHEET - INFECTIOUS SUBSTANCES

SECTION I - INFECTIOUS AGENT

NAME: Ebola virus

SYNONYM OR CROSS REFERENCE: African haemorrhagic fever, Ebola haemorrhagic fever (EHF, Ebola HF), filovirus, EBO virus (EBOV), Zaire ebolavirus (ZEBOV), Sudan ebolavirus (SEBOV), Ivory Coast ebolavirus (ICEBOV), Ebola-Reston (REBOV), Bundibugyo ebolavirus (BEBOV), and Ebola virus disease (1, 2).

CHARACTERISTICS: Ebola was discovered in 1976 and is a member of the Filoviridae family (previously part of Rhabdoviridae family, which were later given a family of their own based on their genetic structure). It is an elongated filamentous molecule, which can vary between 800 – 1000 nm in length, and can reach up to14000 nm long (due to concatamerization) with a uniform diameter of 80 nm (2-5). It contains a helical nucleocapsid, (with a central axis) 20 – 30 nm in diameter, and is enveloped by a helical capsid, 40 – 50 nm in diameter, with 5 nm cross-striations (2-6). The pleomorphic viral fragment may occupy several distinct shapes (e.g., in the shape of a “6”, a “U”, or a circle), and are contained within a lipid membrane (2, 3). Each virion contains one molecule of single-stranded, non-segmented, negative-sense viral genomic RNA (3, 7).

Five Ebola subtypes have been identified: Zaire ebolavirus (ZEBOV), which was first identified in 1976 and is the most virulent; Sudan ebolavirus, (SEBOV; Ivory Coast ebolavirus (ICEBOV); Ebola-Reston (REBOV), and Bundibugyo ebolavirus (BEBOV) (1, 3, 8, 9). Reston was isolated from cynomolgus monkeys from the Philippines in 1989 and is less pathogenic in non-human primates. It was thought to be the only subtype that does not cause infection in humans until 2009, when it was strongly speculated to have been transferred from pigs to humans. Bundibugyo was discovered in 2008, and has been found to be most closely related to the ICEBOV strain (9).

SECTION II – HAZARD IDENTIFICATION

PATHOGENICITY/TOXICITY: The Ebola virions enter the host cells through endocytosis and replication occurs in the cytoplasm. Upon infection, the virus targets the host blood coagulative and immune defence system and leads to severe immunosuppression (6, 10). Early signs of infection are non-specific and flu-like, and may include sudden onset of fever, asthenia, diarrhea, headache, myalgia, arthralgia, vomiting, and abdominal pains (11). Less common early symptoms such as conjunctival injection, sore throat, rashes, and bleeding may also appear. Shock, cerebral oedema, coagulation disorders, and secondary bacterial infection may co-occur with onset of infection (4). Haemorrhaging symptoms begin 4 – 5 days after onset, which includes hemorrhagic conjunctivitis, pharyngitis, bleeding gums, oral/lip ulceration, hematemesis, melena, hematuria, epistaxis, and vaginal bleeding (12). Hepatocellular damage, marrow depression (such as thrombocytopenia and leucopenia), serum transaminase elevation, and proteinuria may also occur. Persons that are terminally ill typically present with obtundation, anuria, shock, tachypnea, normothermia, arthralgia, and ocular diseases (13). Haemorrhagic diathesis is often accompanied by hepatic damage and renal failure, central nervous system involvement, and terminal shock with multi-organ failure (1, 2). Contact with the virus may also result in symptoms such as severe acute viral illness, malaise, and maculopapular rash. Pregnant women will usually abort their foetuses and experience copious bleeding (2). Fatality rates range between 50 – 100%, with most dying of dehydration caused by gastric problems (14). Subtype Ebola-Reston manifests lower levels of pathogenicity in non-human primates and has not been recorded to be infectious in humans; however, sub-clinical symptoms were observed in some people with suspected contact after they developed antibodies against the virus (.

Pathogenicity between different subtypes of Ebola does not differ greatly in that they have all been associated with hemorrhagic fever outbreaks in humans and non-human primates. The Ebola-Zaire and Sudan strains are especially known for their virulence with 53 – 90% fatality rate. Less virulent strains include the Côte d’Ivoire ebolavirus and the Reston strain, and the latter has only been observed to cause sub-clinical infections to humans, with transmission from pigs (9). The major difference between the strains lies in the genome, which can vary by 30 – 40% from each other. This difference might be the cause of the varying ecologic niches of each strain and their evolutionary history. The newly discovered Bundibugyo strain, which caused

a single outbreak in Uganda, has a genome with 30% variance from the other strains. It is most closely related to the Côte d’Ivoire ebolavirus strain; however, it has been found to be more virulent as 37 fatal infections were recorded.

EPIDEMIOLOGY: Occurs mainly in areas surrounding rain forests in central Africa (6) with the exception of Reston which occurs in the Phillipines (9). No predispositions to infection have been identified among infected victims; however, the 20 – 30-year-old age group seems to be particularly susceptible.

Outbreaks:

Democratic Republic of the Congo (formerly Zaire): The first outbreak was recorded in 1976 with 318 cases (88% fatality); in 1995 with 315 cases (81% fatality); in 2001 with 59 cases (75% fatality); in 2003 as two separate outbreaks with 143 cases (90% fatality) and 35 cases (83% fatality), respectively; and recently in 2007 with reports of 372 cases involving 166 deaths (1, 2, 15, 16).

Sudan: The first outbreak was recorded in 1976 with 284 cases (53% fatality); and a second was recorded in 1979 with 34 cases (65% fatality) (1, 2, 15).

Gabon: The first outbreaks were recorded in 1994 with 52 cases (60% fatality); in 1996 as two separate outbreaks with 37 cases (57% fatality) and 60 cases (74% fatality), respectively; and in 2001-2 with 65 cases (82% fatality) (1, 2, 15).

 
Top of Page
Côte-d’Ivoire: Single non-fatal case of a scientist infected during a necropsy of an infected chimpanzee in the Tai Forest (17).

Uganda: Outbreaks were recorded in 2000 with 425 cases (53% fatality); and recently in 2007 with reports of 93 cases involving 22 deaths (2, 15, 18).

Philippine: In 2009, local authorities and international agencies confirmed for the first time that the Ebola Reston virus was strongly likely to have been transmitted from pigs to humans, when it was discovered that 5 out of 77 people who had come in contact with the pigs had developed antibodies to the EBOV virus, no other clinical signs were observed (19).

United States: An outbreak of REBOV in monkeys in 1989 in a shipment of animals from the Philippines, and a second outbreak occurred in 1996 in Texas among animals from the same Phillipine supplier (20).

Western Uganda: The outbreak in 2007 in the townships of Bundibugyo and Kikyo in the Bundibugyo district marked the discovery of the fifth strain of the virus, the Bundibugyo ebolavirus (9). The outbreak lasted for 2 months, with 149 suspected cases and 37 deaths.

HOST RANGE: Humans, various monkey species, chimpanzees, gorillas, baboons, and duikers (1-3, 15, 16, 18, 21-23). The Ebola virus genome was recently discovered in two species of rodents and one species of shrew living in forest border areas, raising the possibility that these animals may be intermediary hosts (24). Other studies of the virus have been done using guinea pig models (25). A survey of small vertebrates captured during the 2001 and 2003 outbreaks in Gabon found evidence of asymptomatic infection in three species of fruit bat (Hypsignathus monstrosus, Epomops franqueti, and Myonycteris torquata) (26).

INFECTIOUS DOSE: 1 – 10 aerosolized organisms are sufficient to cause infection in humans (21).

MODE OF TRANSMISSION: In an outbreak, it is hypothesized that the first patient becomes infected as a result of contact with an infected animal (15). Person-to-person transmission occurs via close personal contact with an infected individual or their body fluids during the late stages of infection or after death (1, 2, 15, 27). Nosocomial infections can occur through contact with infected body fluids due to the reuse of unsterilized syringes, needles, or other medical equipment contaminated with these fluids (1, 2). Humans may be infected by handling sick or dead non-human primates and are also at risk when handling the bodies of deceased humans in preparation for funerals, suggesting possible transmission through aerosol droplets (2, 6, 28). In the laboratory, infection through small-particle aerosols has been demonstrated in primates, and airborne spread among humans is strongly suspected, although it has not yet been conclusively demonstrated (1, 6, 13). The importance of this route of transmission is not clear. Poor hygienic conditions can aid the spread of the virus (6).

INCUBATION PERIOD: Two to 21 days, more often 4 – 9 days (1, 13, 14).

COMMUNICABILITY: Communicable as long as blood, secretions, organs, or semen contain the virus. Ebola virus has been isolated from semen 61 days after the onset of illness, and transmission through semen has occurred 7 weeks after clinical recovery (1, 2).

SECTION III - DISSEMINATION

RESERVOIR: The natural reservoir of Ebola is unknown (1, 2). Antibodies to the virus have been found in the serum of domestic guinea pigs, with no relation to human transmission (29). The virus can be replicated in some bat species native to the area where the virus is found, thus certain bat species may prove to be the natural hosts (26).

ZOONOSIS: Probably transmitted from animals (non-human primates and/or bats) (2, 15, 26).

VECTORS: Unknown.

 
Top of Page
SECTION IV – STABILITY AND VIABILITY

DRUG SUSCEPTIBILITY: Unknown. S-adenosylhomocysteine hydrolase inhibitors have been found to have complete mortality protection in mice infected with a lethal dose of Ebola virus (30).

DRUG RESISTANCE: There are no known antiviral treatments available for human infections.

SUSCEPTIBILITY TO DISINFECTANTS: Ebola virus is susceptible to sodium hypochlorite, lipid solvents, phenolic disinfectants, peracetic acid, methyl alcohol, ether, sodium deoxycholate, 2% glutaraldehyde, 0.25% Triton X-100, β-propiolactone, 3% acetic acid (pH 2.5), formaldehyde and paraformaldehyde, and detergents such as SDS (20, 21, 31-34).

PHYSICAL INACTIVATION: Ebola are moderately thermolabile and can be inactivated by heating for 30 minutes to 60 minutes at 60ºC, boiling for 5 minutes, gamma irradiation (1.2 x106 rads to 1.27 x106 rads), and/or UV radiation (3, 6, 20, 32, 33).

SURVIVAL OUTSIDE HOST: The virus can survive in liquid or dried material for a number of days (23). Infectivity is found to be stable at room temperature or at 4°C for several days, and indefinitely stable at -70°C (6, 20). Infectivity can be preserved by lyophilisation.

SECTION V – FIRST AID / MEDICAL

SURVEILLANCE: Monitor anyone suffering from an acute febrile illness that has recently travelled to rural sub-Saharan Africa, especially if haemorrhagic manifestations occur (3). Diagnosis can be quickly done in an appropriately equipped laboratory using a multitude of approaches including ELISA based techniques to detect anti-Ebola antibodies or viral antigens (12), RT-PCR to detect viral RNA, immunoelectron microscopy to detect Ebola virus particles in tissues and cells, and indirect immunofluorescence to detect antiviral antibodies (1, 2, 12, 21). It is useful to note that the Marburg virus is morphologically indistinguishable from the Ebola virus, and laboratory surveillance of Ebola is extremely hazardous and should be performed in a Containment Level 4 facility (1, 2, 12, 35).

Note: All diagnostic methods are not necessarily available in all countries.

FIRST AID/TREATMENT: There is no effective antiviral treatment (23, 26). Instead, treatment is supportive, and is directed at maintaining renal function and electrolyte balance and combating haemorrhage and shock (15). Transfusion of convalescent serum may be beneficial (3). Post-exposure treatment with a nematode-derived anticoagulation protein and a recombinant vesicular stomatitis virus vaccine expressing the Zaire Ebola virus glycoprotein have been shown to have 33% and 50% efficacy, respectively, in humans (4). Recent studies have shown that small interfering RNAs (siRNAs) can be potentially effective in silencing Zaire Ebola virus RNA polymerase L, and treatments in rhesus macaque monkeys have resulted in 100% efficacy when administered everyday for 6 days; however, delivery of the nucleic acid still remains an obstacle.

IMMUNIZATION: None (23).

PROPHYLAXIS: None. Management of the Ebola virus is solely based on isolation and barrier-nursing with symptomatic and supportive treatments (4).

SECTION VI - LABORATORY HAZARDS

LABORATORY-ACQUIRED INFECTIONS: One reported near-fatal case following a minute finger prick in an English laboratory (1976) (36). A Swiss zoologist contracted Ebola virus after performing an autopsy on a chimpanzee in 1994 (2, 37). An incident in Germany in 2009 when a laboratory scientist pricked herself with a needle that had just been used to infect a mouse with Ebola, however infection has not be confirmed. Additional incidents were recorded in the US in 2004, and a fatal case in Russia in 2004 (4).

SOURCES/SPECIMENS: Blood, serum, urine, respiratory and throat secretions, semen, and organs or their homogenates from human or animal hosts (1, 2, 35). Human or animal hosts, including non-human primates, may represent a further source of infection (35).

PRIMARY HAZARDS: Accidental parenteral inoculation, respiratory exposure to infectious aerosols and droplets, and/or direct contact with broken skin or mucous membranes (35).

SPECIAL HAZARDS: Work with, or exposure to, infected non-human primates, rodents, or their carcasses represents a risk of human infection (35).

SECTION VII – EXPOSURE CONTROLS / PERSONAL PROTECTION

RISK GROUP CLASSIFICATION: Risk Group 4 (38).

CONTAINMENT REQUIREMENTS: Containment Level 4 facilities, equipment, and operational practices for work involving infectious or potentially infectious materials, animals, and cultures.

PROTECTIVE CLOTHING: Personnel entering the laboratory must remove street clothing, including undergarments, and jewellery, and change into dedicated laboratory clothing and shoes, or don full coverage protective clothing (i.e., completely covering all street clothing). Additional protection may be worn over laboratory clothing when infectious materials are directly handled, such as solid-front gowns with tight fitting wrists, gloves, and respiratory protection. Eye protection must be used where there is a known or potential risk of exposure to splashes (39).

OTHER PRECAUTIONS: All activities with infectious material should be conducted in a biological safety cabinet (BSC) in combination with a positive pressure suit, or within a class III BSC line. Centrifugation of infected materials must be carried out in closed containers placed in sealed safety cups, or in rotors that are unloaded in a biological safety cabinet. The integrity of positive pressure suits must be routinely checked for leaks. The use of needles, syringes, and other sharp objects should be strictly limited. Open wounds, cuts, scratches, and grazes should be covered with waterproof dressings. Additional precautions should be considered with work involving animal activities (39).

 
Top of Page
SECTION VIII - HANDLING AND STORAGE

SPILLS: Allow aerosols to settle and, wearing protective clothing, gently cover spill with paper towels and apply suitable disinfectant, starting at the perimeter and working towards the centre. Allow sufficient contact time before clean up (39).

DISPOSAL: Decontaminate all materials for disposal from the containment laboratory by steam sterilisation, chemical disinfection, incineration or by gaseous methods. Contaminated materials include both liquid and solid wastes (39).

STORAGE: In sealed, leak-proof containers that are appropriately labelled and locked in a Containment Level 4 laboratory (39).

SECTION IX – REGULATORY AND OTHER INFORMATION

REGULATORY INFORMATION: The import, transport, and use of pathogens in Canada is regulated under many regulatory bodies, including the Public Health Agency of Canada, Health Canada, Canadian Food Inspection Agency, Environment Canada, and Transport Canada. Users are responsible for ensuring they are compliant with all relevant acts, regulations, guidelines, and standards.

UPDATED: August 2010.

PREPARED BY: Pathogen Regulation Directorate, Public Health Agency of Canada.

Although the information, opinions and recommendations contained in this Pathogen Safety Data Sheet are compiled from sources believed to be reliable, we accept no responsibility for the accuracy, sufficiency, or reliability or for any loss or injury resulting from the use of the information. Newly discovered hazards are frequent and this information may not be completely up to date.

Copyright

Public Health Agency of Canada, 2010

Canada

REFERENCES:

 Plague. (2004). In R. G. Darling, & J. B. Woods (Eds.), USAMRIID's Medical Management of Biological Casualties Handbook (5th ed., pp. 40-44). Fort Detrick M.D.: USAMRIID. 
 
 Acha, P. N., & Szyfres, B. (2003). In Pan american Health Organization (Ed.), Zoonoses and Communicable Diseases Common to Man and Animals (3rd ed., pp. 142-145). Washington D.C.: Pan American Health Organization. 
 
 Sanchez, A. (2001). Filoviridae: Marburg and Ebola Viruses. In D. M. Knipe, & P. M. Howley (Eds.), Fields virology (4th ed., pp. 1279-1304). Philadelphia, PA.: Lippencott-Ravenpp. 
 
 Feldmann, H. (2010). Are we any closer to combating Ebola infections? Lancet, 375(9729), 1850-1852. doi:10.1016/S0140-6736(10)60597-1. 
 
 Beran, G. W. (Ed.). (1994). Handbook of Zoonosis, Section B: Viral (2nd ed.). Boca Raton, Florida: CRC Press, LLC. 
 
 Mwanatambwe, M., Yamada, N., Arai, S., Shimizu-Suganuma, M., Shichinohe, K., & Asano, G. (2001). Ebola hemorrhagic fever (EHF): mechanism of transmission and pathogenicity. Journal of Nippon Medical School = Nihon Ika Daigaku Zasshi, 68(5), 370-375. 
 
 Sanchez, A., Kiley, M. P., Klenk, H. D., & Feldmann, H. (1992). Sequence analysis of the Marburg virus nucleoprotein gene: comparison to Ebola virus and other non-segmented negative-strand RNA viruses. The Journal of General Virology, 73 ( Pt 2)(Pt 2), 347-357. 
 
 Takada, A., & Kawaoka, Y. (2001). The pathogenesis of Ebola hemorrhagic fever. Trends in Microbiology, 9(10), 506-511. 
 
 Towner, J. S., Sealy, T. K., Khristova, M. L., Albarino, C. G., Conlan, S., Reeder, S. A., Quan, P. L., Lipkin, W. I., Downing, R., Tappero, J. W., Okware, S., Lutwama, J., Bakamutumaho, B., Kayiwa, J., Comer, J. A., Rollin, P. E., Ksiazek, T. G., & Nichol, S. T. (2008). Newly discovered ebola virus associated with hemorrhagic fever outbreak in Uganda. PLoS Pathogens, 4(11), e1000212. doi:10.1371/journal.ppat.1000212 .
 
 Harcourt, B. H., Sanchez, A., & Offermann, M. K. (1999). Ebola virus selectively inhibits responses to interferons, but not to interleukin-1beta, in endothelial cells. Journal of Virology, 73(4), 3491-3496. 
 
 Bwaka, M. A., Bonnet, M. J., Calain, P., Colebunders, R., De Roo, A., Guimard, Y., Katwiki, K. R., Kibadi, K., Kipasa, M. A., Kuvula, K. J., Mapanda, B. B., Massamba, M., Mupapa, K. D., Muyembe-Tamfum, J. J., Ndaberey, E., Peters, C. J., Rollin, P. E., Van den Enden, E., & Van den Enden, E. (1999). Ebola hemorrhagic fever in Kikwit, Democratic Republic of the Congo: clinical observations in 103 patients. The Journal of Infectious Diseases, 179 Suppl 1, S1-7. doi:10.1086/514308. 
 
 Zilinskas, R. A. (Ed.). (2000). Biololgical Warfare - Modern Offense and Defense. Boulder, Colorado, USA: Lynne Rienner Publishers, Inc. 
 
 Feigin, R. D. (Ed.). (2004). Textbook of Pediatric Infectious Diseases (5th ed.). Philadelphia, USA: Elsevier, Inc. 
 
 Casillas, A. M., Nyamathi, A. M., Sosa, A., Wilder, C. L., & Sands, H. (2003). A current review of Ebola virus: pathogenesis, clinical presentation, and diagnostic assessment. Biological Research for Nursing, 4(4), 268-275. 
 
 Bausch, D. G., Jeffs B.S.A.G, & Boumandouki, P. (2008). Treatment of Marburg and Ebola haemorrhagic fevers: a strategy for testing new drugs and vaccines under outbreak conditions. Antiviral Res., 78(1), 150-161. 
 
 WHO Disease Outbreak News - Ebola Haemorrhagic Fever in the Democratic Republic of Congo. (2007). , 2008. 
 
 Formenty, P., Boesch, C., Wyers, M., Steiner, C., Donati, F., Dind, F., Walker, F., & Le Guenno, B. (1999). Ebola virus outbreak among wild chimpanzees living in a rain forest of Cote d'Ivoire. The Journal of Infectious Diseases, 179 Suppl 1, S120-6. doi:10.1086/514296. 
 
 WHO Disease Outbreak News - Ebola Haemorrhagic Fever in Uganda - Update. (2007). , 2008 .
 
 Morris, K. (2009). First pig-to-human transmission of Ebola Reston virus.9(3), 148. 
 
 Evans, A. S., & Kaslow, R. A. (Eds.). (1997). Viral Infections of Humans - Epidemiology and Control (4th ed.). New York, NY: Plenum Publishing Corporation. 
 
 Franz, D. R., Jahrling, P. B., McClain, D. J., Hoover, D. L., Byrne, W. R., Pavlin, J. A., Christopher, G. W., Cieslak, T. J., Friedlander, A. M., & Eitzen E.M., J. (2001). Clinical recognition and management of patients exposed to biological warfare agents. Clinics in Laboratory Medicine, 21(3), 435-473. 
 
 Bray, M. (2003). Defense against filoviruses used as biological weapons. Antiviral Research, 57(1-2), 53-60. 
 
 Leroy, E. M., Rouquet, P., Formenty, P., Souquière, S., Kilbourne, A., Froment, J. -., Bermejo, M., Smit, S., Karesh, W., Swanepoel, R., Zaki, S. R., & Rollin, P. E. (2004). Multiple Ebola Virus Transmission Events and Rapid Decline of Central African Wildlife. Science, 303(5656), 387-390. 
 
 Morvan, J. M., Nakouné, E., Deubel, V., & Colyn, M. (2000). Ebola virus and forest ecosystem. [Écosystèmes forestiers et virus Ebola] Bulletin De La Societe De Pathologie Exotique, 93(3), 172-175. 
 
 Connolly, B. M., Steele, K. E., Davis, K. J., Geisbert, T. W., Kell, W. M., Jaax, N. K., & Jahrling, P. B. (1999). Pathogenesis of experimental Ebola virus infection in guinea pigs. The Journal of Infectious Diseases, 179 Suppl 1, S203-17. doi:10.1086/514305. 
 
 Leroy, E. M., Kumulungui, B., Pourrut, X., Rouquet, P., Hassanin, A., Yaba, P., Délicat, A., Paweska, J. T., Gonzalez, J. -., & Swanepoel, R. (2005). Fruit bats as reservoirs of Ebola virus. Nature, 438(7068), 575-576. 
 
 Arthur, R. R. (2002). Ebola in Africa--discoveries in the past decade. Euro Surveillance : Bulletin Europeen Sur Les Maladies Transmissibles = European Communicable Disease Bulletin, 7(3), 33-36. 
 
 Hewlett, B. S., & Amolat, R. P. (2003). Cultural contexts of Ebola in Northern Uganda. Emerging Infectious Diseases, 9(10), 1242-1248. 
 
 Stansfield, S. K., Scribner, C. L., Kaminski, R. M., Cairns, T., McCormick, J. B., & Johnson, K. M. (1982). Antibody to Ebola virus in guinea pigs: Tandala, Zaire. The Journal of Infectious Diseases, 146(4), 483-486. 
 
 Huggins, J., Zhang, Z. X., & Bray, M. (1999). Antiviral drug therapy of filovirus infections: S-adenosylhomocysteine hydrolase inhibitors inhibit Ebola virus in vitro and in a lethal mouse model. The Journal of Infectious Diseases, 179 Suppl 1, S240-7. doi:10.1086/514316. 
 
 Loutfy, M. R., Assmar, M., Burgess, D. C. H., & Kain, K. C. (1998). Effects of viral hemorrhagic fever inactivation methods on the performance of rapid diagnostic tests for Plasmodium falciparum. Journal of Infectious Diseases, 178(6), 1852-1855. 
 
 Elliott, L. H., McCormick, J. B., & Johnson, K. M. (1982). Inactivation of Lassa, Marburg, and Ebola viruses by gamma irradiation. Journal of Clinical Microbiology, 16(4), 704-708. 
 
 Mitchell, S. W., & McCormick, J. B. (1984). Physicochemical inactivation of Lassa, Ebola, and Marburg viruses and effect on clinical laboratory analyses. Journal of Clinical Microbiology, 20(3), 486-489. 
 
 Mahanty, S., Kalwar, R., & Rollin, P. E. (1999). Cytokine measurement in biological samples after physicochemical treatment for inactivation of biosafety level 4 viral agents. Journal of Medical Virology, 59(3), 341-345. 
 
 Biosafety in Microbiological and Biomedical Laboratories (BMBL) (2007). In Richmond J. Y., McKinney R. W. (Eds.), . Washington, D.C.: Centers for Disease Control and Prevention. 
 
 Emond, R. T. D., Evans, B., Bowen, E. T. W., & Lloyd, G. (1977). A case of Ebola virus infection. British Medical Journal, 2(6086), 541-544. 
 
 Formenty, P., Hatz, C., Le Guenno, B., Stoll, A., Rogenmoser, P., & Widmer, A. (1999). Human infection due to Ebola virus, subtype Cote d'Ivoire: Clinical and biologic presentation. Journal of Infectious Diseases, 179(SUPPL. 1), S48-S53. 
 
 Human pathogens and toxins act. S.C. 2009, c. 24, Second Session, Fortieth Parliament, 57-58 Elizabeth II, 2009. (2009). 
 
 Public Health Agency of Canada. (2004). In Best M., Graham M. L., Leitner R., Ouellette M. and Ugwu K. (Eds.), Laboratory Biosafety Guidelines (3rd ed.). Canada: Public Health Agency of Canada.

http://www.prisonplanet.com/if-ebola-hits-u-s-even-healthy-americans-will-be-quarantined.html


If Ebola Hits U.S., Even Healthy Americans Will be Quarantined





“Well persons” who “do not show symptoms” would be forcibly detained

Paul Joseph Watson
Prison Planet.com
July 30, 2014


With concerns growing over the deadly Ebola virus, which has killed 670 people in West Africa, preparations are already underway in the United States, where even healthy Americans will be subjected to forced quarantine in the event of an Ebola pandemic.
















Related posts:

1. Deadly Ebola virus spreading in West Africa
   
2. Ebola Victim On The Run In West Africa Capital
   
3. ALERT: Delivered By Airplane: Ebola Now Threatens 21 Million People In Major Metro Area
   
4. Briton quarantined as killer flu spreads
   
5. Has Ebola Escaped Africa? Patient Isolated In Canada
   

This article was posted: Wednesday, July 30, 2014 at 6:07 am

'Well persons who do not show syptoms would be forcibly detained'

Much like the 30,000 they're 'hunting' as we speak?

http://www.mirror.co.uk/news/world-news/ebola-spiders-web-infection-growing-3939374

Soon to arrive at 33* N., and to think I've always cringed when someone uses the term Hotlanta.   

Source: Flight leaves for Liberia to evacuate Americans infected with Ebola

http://www.cnn.com/2014/07/31/health/ebola-outbreak/index.html

http://www.prisonplanet.com/ebola-what-youre-not-being-told.html

Ebola – What You’re Not Being Told

• 
  

SCG News
July 31, 2014
There is something very, very important that the corporate media and public health officials are not telling you regarding the Ebola outbreak in west Africa.

https://www.youtube.com/watch?feature=player_embedded&v=JnQVUf775VE

STOCK UP NOW!
Don't forget Vitamin C and D3!!

http://beforeitsnews.com/alternative/2014/07/breaking-news-deadly-ebola-virus-confirmed-in-atlanta-georgia-3003924.html

Cure For Ebola They Don’t Want You To Know About!!

Friday, August 1, 2014 15:25



By Susan Duclos
 
“We are all one plane ride away from a cataclysm.”- Dr. Rima Laibow, MD
 
Medical Director of the Natural Solutions Foundation, Doctor Rima Laibow, has an urgent message, one she has sent to the presidents of the four Ebola stricken countries, “including a copy to the President of what may well be the next country afflicted, the United States since an Ebola-stricken volunteer is being flown to Atlanta for treatment, according to her latest video and an article at Sky Ships Over Cashiers, with what she considers a proven cure for Ebola, but one TPTB don’t want us to know about.
 
And the kill rate for this disease of convenience, genetically engineered to be more deadly than ever before, just happens, I am sure coincidentally, to be the exact number depopulationists like Bill Gates and George Soros have wet dreams about: 90%.
 
The US government study (declassified in 2009) which showed definitively that Nano Silver at 10 PPM is the definitive prevention and therapy for Ebola virus “somehow” got “overlooked.” We do not know how long before that the work actually took place, but the US civilian authorities knew not later than 2009 that there is a cure, treatment and prevention for Ebola virus. . . .
 
Listen to her, go read the entire piece over at Sky Ships and ask youself after reading it, why the study from 2009 was classified in the first place and why after it was declassified, is everyone still ignoring it?
 
[Update] H/T Neo, 2005 study found here (94 pages)
 
Sign Up To Live Free or Die and Susan Duclos’ News Letter! For all our latest articles delivered once a day.